Custom Health Holdings Inc (TSX:CHLT) said early results from its commercial program with BKC Pain Specialists & Regenerative Medicine Clinic in Ohio showed patients achieved approximately 94% medication adherence.
The AI-enabled healthcare technology company said the program connects pharmacy services, in-home medication technology and pharmacist-led clinical support for patients managing chronic pain.
Based on internal company data, more than 7,400 patient survey responses were captured through Custom Health's connected platform over a six-month period. Participants in the BKC program take an average of 6.6 medications, the company said.
Custom Health provides participating BKC patients with prescription fulfillment and pharmacy services through its Ohio operations, along with connected in-home medication management technology and ongoing pharmacist-led support. Its spencer technology captures medication-taking activity and facilitates personalized patient engagement, while AdhereNet connects those insights with the company's clinical team and BKC's treating physicians.
Pharmacists use medication-taking activity and patient responses to personalize follow-up questions about pain, daily functioning and potential medication-related concerns, rather than relying on standardized surveys. The company said this helps identify adherence issues, review potential risks and coordinate follow-up with BKC's physicians. All prescribing and treatment decisions remain with BKC's authorized clinicians.
"Healthcare has historically operated in disconnected environments. The physician manages the treatment plan, the pharmacy dispenses medication, and the patient is left to navigate much of the journey between visits," said Shane Bishop, CEOof Custom Health.
"Our work with BKC demonstrates a different approach. By connecting physicians, pharmacists and patients through AdhereNet, we are creating continuous visibility into medication use and the opportunity to act earlier when patients need attention."
Dr Adil Katabay, Founder and Medical Director of BKC, said greater visibility into medication use, pain levels and daily functioning helps his clinic identify concerns earlier and make more informed treatment decisions.
"Based on the encouraging initial results, we look forward to expanding the program across our broader patient population," Katabay said.
Custom Health said the early results support plans to expand the program across BKC's broader patient population. The company also pointed to the potential to replicate the model across additional pain management practices and other specialty providers in the US.
It intends to continue expanding the program with BKC and evaluate its impact on medication adherence, patient engagement, clinical workflows and patient outcomes.
